Lupin gets US FDA EIR with VAI classification for Goa facility
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.2 pts more than Nifty Midcap 150 and 0.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin received an Establishment Inspection Report (EIR) from the US FDA for its Goa facility with a satisfactory Voluntary Action Indicated (VAI) classification. The inspection took place from November 10 to November 21, 2025. VAI classification means no official action is required, reflecting positively on quality and compliance standards. MD Nilesh Gupta called it a sign of continued focus on quality excellence.
Positive signal for regulatory compliance and US market operations; supports investor confidence in Lupin's manufacturing quality.